200 results on '"Kuk, Cynthia"'
Search Results
2. Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis
3. DEVELOPMENT AND EXTERNAL VALIDATION OF NIMBLE, AN ARTIFICIAL INTELLIGENCE-BASED TOOL TO PREDICT PROGRESSION IN NON-MUSCLE INVASIVE BLADDER CANCER: A RETROSPECTIVE MULTI-INSTITUTIONAL COHORT STUDY
4. ABC: Artificial Intelligence for Bladder Cancer grading system
5. A semi-supervised learning approach for bladder cancer grading
6. The impact of grading scheme on non-muscle invasive bladder cancer progression: potential utility of hybrid grading schemes
7. Carcinoma In Situ (CIS): Is There a Difference in Efficacy between Various BCG Strains? A Comprehensive Review of the Literature
8. Long‐term outcomes and cost savings of office fulguration of papillary Ta low‐grade bladder cancer.
9. Non-muscle-invasive bladder cancer - understanding and managing risk
10. PD13-05 LONG-TERM ONCOLOGICAL OUTCOMES OF OFFICE-BASED FULGURATION OF TA LOW-GRADE NON MUSCLE INVASIVE BLADDER CANCER: A LARGE SINGLE CENTER SERIES
11. MP61-02 DEVELOPMENT, MULTI-INSTITUTIONAL EXTERNAL VALIDATION, AND ALGORITHMIC AUDIT OF SEPERA - AN ARTIFICIAL INTELLIGENCE-BASED SIDE-SPECIFIC EXTRA-PROSTATIC EXTENSION RISK ASSESSMENT TOOL FOR PATIENTS UNDERGOING RADICAL PROSTATECTOMY
12. PD09-03 INVERSE PROBABILITY TREATMENT WEIGHTING COMPARISON OF RADICAL CYSTECTOMY TO TRIMODALITY THERAPY FOR CT2-CT4 MUSCLE INVASIVE BLADDER CANCER
13. Clinical Presentation, Diagnosis and Staging
14. The Importance of Surgeon Characteristics on Impacting Oncologic Outcomes for Patients Undergoing Radical Cystectomy
15. PD42-01 PROPENSITY MATCHED COMPARISON OF RADICAL CYSTECTOMY WITH TRIMODALITY THERAPY FOR MUSCLE INVASIVE BLADDER CANCER (MIBC): A MULTI-INSTITUTIONAL STUDY
16. PD26-05 HOW LONG SHOULD WE FOLLOW LOW GRADE TA NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC)? A LARGE RETROSPECTIVE SINGLE INSTITUTION ANALYSIS
17. Multi-institutional matched comparison of radical cystectomy to trimodality therapy for muscle-invasive bladder cancer.
18. MP16-11 PATHOLOGICAL FEATURES AND CLINICAL BEHAVIOR OF LYNCH SYNDROME-ASSOCIATED BLADDER CANCER
19. MP43-17 DIFFERENCES IN GLEASON SCORE (GS) DISTRIBUTION AND TUMOR AGGRESSIVENESS IN LARGE COHORTS OF ASIAN AND CAUCASIAN MEN
20. PD65-07 LIFESTYLE MODIFICATIONS AND THEIR EFFECT ON SERUM PROSTATE SPECIFIC ANTIGEN LEVELS
21. PROPENSITY-MATCHED COMPARISON OF SURVIVAL OUTCOMES IN PATIENTS UNDERGOING RADICAL CYSTECTOMY VERSUS BLADDER PRESERVING TRIMODAL THERAPY: PD39-08
22. MOLECULAR TUMOR GRADING OF NON MUSCLE INVASIVE BLADDER CANCER BASED ON WHOLE TRANSCRIPTOME ANALYSIS: PD11-09
23. Not all gleason pattern 4 prostate cancers are created equal: A study of latent prostatic carcinomas in a cystoprostatectomy and autopsy series
24. Clinical Presentation, Diagnosis and Staging
25. MP68-04 A FIVE—GENE DNA—METHYLATION BIOMARKER PANEL SENSITIVELY DETECTS BLADDER CANCER AND DISCRIMINATES BETWEEN HIGH—GRADE AND LOW—GRADE DISEASE IN VOIDED URINE
26. MP68-05 RESOLVING INTER-PATHOLOGIST VARIATION IN THE ASSIGNMENT OF GRADE USING WHOLE TRANSCRIPTOME ANALYSIS FOR PATIENTS WITH UROTHELIAL BLADDER CANCER
27. MP61-01 FUNCTIONAL ROLE OF THE KALLIKREIN 6 REGION OF THE KALLIKREIN LOCUS IN GENETIC PREDISPOSITION FOR AGGRESSIVE (GLEASON ≥8) PROSTATE CANCER: FINE-MAPPING AND METHYLATION STUDY IN A CANADIAN COHORT AND THE SWISS ARM OF THE EUROPEAN RANDOMIZED STUDY FOR PROSTATE CANCER SCREENING
28. Combined inhibition of MEK and mTOR has a synergic effect on angiosarcoma tumorgrafts
29. Upper urinary tract and urethral recurrences following radical cystectomy: review of risk factors and outcomes between centres with different follow-up protocols
30. PERSONALIZING BLADDER CANCER CARE: RESULTS OF A MULTIDISCIPLINARY BLADDER CANCER CLINIC: MP65-01
31. MULTI-INSTITUTIONAL QUALITY CARE INITIATIVE TO IMPROVE THE CARE OF PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER: MP60-12
32. FINE-MAPPING OF THE KALLIKREIN REGION AND ITS ROLE IN PROSTATE CANCER AGGRESSIVENESS: RESULTS FROM A CANADIAN COHORT AND THE EUROPEAN RANDOMIZED STUDY FOR PROSTATE CANCER SCREENING: MP49-20
33. Trimodal therapy in muscle invasive bladder cancer management
34. Sequential administration of Bacillus Calmette-Guerin (BCG) and Electromotive Drug Administration (EMDA) of mitomycin C (MMC) for the treatment of high-grade nonmuscle invasive bladder cancer after BCG failure
35. Transurethral Needle Ablation of the Prostate
36. Prevalence of Prostate Cancer on Autopsy: Cross-Sectional Study on Unscreened Caucasian and Asian Men
37. Does patient age affect survival after radical cystectomy?
38. Upstaging of urothelial cancer at the time of radical cystectomy: factors associated with upstaging and its effect on outcome
39. Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi-institutional study
40. Long-term follow-up of T1 high-grade bladder cancer after intravesical bacille Calmette-Guérin treatment
41. A noninvasive urine-based methylation biomarker panel to detect bladder cancer and discriminate cancer grade
42. MP73-01 SEQUENTIAL ADMINISTRATION OF BACILLUS CALMETTE-GUERIN (BCG) AND ELECTROMOTIVE DRUG ADMINISTRATION (EMDA) OF MITOMYCIN C (MMC) FOR THE TREATMENT OF HIGH GRADE NON MUSCLE INVASIVE BLADDER CANCER AFTER BCG FAILURE
43. Optimal timing of radical cystectomy in T1 high-grade bladder cancer
44. Human tissue kallikrein expression in the stratum corneum and serum of atopic dermatitis patients
45. Are there differences among Bacillus Calmette-Guérin (BCG) strains regarding their clinical efficacy in the treatment of non-muscle invasive bladder cancer? The jury is still out but the answer is likely no
46. Further Evidence of Differences in Prostate Cancer Biomarkers Between Caucasian and Asian Men
47. PD18-07 A NON-INVASIVE URINE-BASED METHYLATION BIOMARKER PANEL FOR BLADDER CANCER DETECTION
48. Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic
49. MP65-11 RNA SEQUENCING IDENTIFIES 3 DIFFERENT MOLECULAR GRADES AND IMMUNE CHECKPOINT CASCADES WITH DISTINCT CLINICAL BEHAVIOUR IN NON MUSCLE INVASIVE BLADDER CANCER
50. RNA-sequencing to identify three different molecular grades and immune checkpoint cascades with distinct clinical behaviour in NMIBC.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.